Patient Characteristics
| Patient no. | Sex | Age (y) | Diagnosis | Disease stage | Mutation | Splenomegaly and splenic volume | Treatment | Follow-up PET/CT | CSCR4 IHC staining |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 73 | PV | Initial diagnosis | JAK2 V617F | Yes (532 cm3) | Ruxolitinib | Yes | Yes |
| 2 | F | 66 | ET | Initial diagnosis | JAK2 V617F | No (226 cm3) | None | No | Yes |
| 3 | M | 37 | ET | Initial diagnosis | CALR | Yes (260 cm3) | None | No | Yes |
| 4 | F | 51 | ET | Stable disease | JAK2 V617F | No (228 cm3) | Anagrelide | No | Yes |
| 5 | M | 60 | ET | Initial diagnosis | CALR | Yes (450 cm3) | Hydroxyurea | Yes | Yes |
| 6 | M | 64 | PMF | Initial diagnosis | JAK2 V617F | Yes (689 cm3) | Ruxolitinib | Yes | Yes |
| 7 | M | 58 | PV | Stable disease | JAK2 V617F | No (280 cm3) | Hydroxyurea | No | Yes |
| 8 | F | 62 | PMF | Progressive disease | JAK2 V617F | Yes (508 cm3) | Ruxolitinib | No | Yes |
| 9 | F | 42 | PMF | Initial diagnosis | None detected | No (250 cm3) | None | No | No |
| 10 | F | 63 | ET | Stable disease | JAK2 V617F | Yes (625 cm3) | Hydroxyurea | No | No |
| 11 | M | 58 | PMF | Initial diagnosis | JAK2 V617F | No (214 cm3) | None | No | Yes |
| 12 | F | 52 | ET | Stable disease | None detected | No (180 cm3) | Anagrelide | No | No |
IHC = immunohistochemistry; PV = polycythemia vera; ET = essential thrombocythemia; PMF = primary myelofibrosis; CALR = calreticulin.